Holds one active US DMF and one valid CEP for ciclesonide, filing since 2009. Its 2022 FDA inspection closed as VAI, and its GMP is recognised in 3 markets.
Holds one active US DMF and one valid CEP for ciclesonide, filing since 2025. Its 2023 FDA inspection closed as VAI.
Holds 4 valid CEPs for ciclesonide, filing since 2022. Its 2025 FDA inspection closed as VAI, and its GMP is recognised in 34 markets.
Holds one active US DMF for ciclesonide, filing since 2010. Its 2026 FDA inspection closed as VAI, and its GMP is recognised in 1 market.
Holds 2 active US DMFs for ciclesonide, filing since 2023. Its 2019 FDA inspection closed as VAI.
Holds one active US DMF for ciclesonide, filing since 2003.
Registered with PMDA (Japan) for ciclesonide.
Registered with SFDA (Saudi Arabia) for ciclesonide.
The names are listed below. The filings, inspection history and GMP certificates behind each one are available with a free account.
The order is set by active filings weighted by regulator, inspection outcomes and their recency, breadth of GMP recognition, and evidence of real exports, less any open risk flags. Every factor appears on the card it produced. Read the full method.
Tell us which markets you need to file in. These suppliers come back tiered for those markets, with the price corridor and an RFI sheet.
Start for free